Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
271 Leser
Artikel bewerten:
(1)

Dyad Medical's SaaS based AI for cardiac imaging fundraising exceeds $3.5MM

BOSTON, Oct. 1, 2020 /PRNewswire/ -- Dyad Medical, Inc., a groundbreaking medical image analysis platform delivering cloud-based artificial intelligence (AI)-based analysis, announced after just 90 days, the closing of its oversubscribed Series Seed funding round led by The Unofficial Syndicate, with participation by Social Starts L.P., and local angel investors. Along with grants from the NIH, this brings Dyad's total funding to more than $3.5MM.

Dyad, a recent Mass Challenge grad, will use the funding to enhance its patent-pending cardiac imaging software, to accelerate its FDA clearance path and expand their team to prepare for customer deployments. Dyad's cloud-native platform increases the accuracy and efficiency of cardiac image analysis providing cardiologist and clinicians with near real-time observations that, prior to Dyad, in many cases were invisible to the human eye and time consuming to detail.

"We are the only solution that provides cardiologists with insights on every scan they perform, regardless of the modality used and what part of the heart they scan," says Dr. Ronny Shalev, co-founder and CEO of Dyad Medical. "We are clear on our goal to provide universal access to expert-level observations by teaching computers to automatically analyze medical images. The Dyad platform, will provide instantaneous cardiac image interpretations globally via the web, accessible by any device, which for a clinician is like having 1000's of expert second opinions for them to consider in their diagnoses - all in real-time."

"The combination of artificial intelligence, a brain trust of distinguished scientific advisors, and a cloud-based solution that delivers the only four modality cardiac analysis in the market is game changing. We believe this will become the gold standard in cardiac care and we are excited to help them bring this technology to market," said Jayme Fishman, Co-founder of The Unofficial Syndicate. "My co-founder, Harry Scott, brought this deal to our consortium and will lead Dyad's Advisory board as we help them move to commercialization."

"We believe Dyad will transform the cardiac imaging field by placing cutting-edge technology within cardiologists' current workflow to efficiently drive faster and more accurate diagnoses," said Emi Gonzalez, Principal at Social Starts.

About Dyad Medical
Dyad Medical develops clinical applications using cloud-based artificial intelligence aimed at enabling doctors to more efficiently interpret medical image content from anywhere in the world. It is powered by the expertise of a global community of clinicians who train the model, effectively offering practitioners "thousands of second opinions" in real-time. Within the digital diagnostics arena, Dyad Medical's core focus is on cardiac imaging because more people die as a result of cardiovascular disease than all types of cancer, diabetes, and accidents combined. www.dyadmed.com

About The Unofficial Syndicate
Irreverently named The Unofficial Syndicate is an active angel investment group of "non-members" known for high touch, thoughtful analysis and speed of decision making in finding and nurturing Seed stage companies navigate their formative years. www.TheUnofficialSyndicate.com

About Social Starts
Social Starts is a venture capital partnership with a uniquely data-driven approach to investing in moment-of-inception and Series A financing rounds. Focusing on companies that leverage social and mobile technologies with a particular emphasis on the emerging science and technology of health and happiness www.SocialStarts.com.

Media Contact:
Ronny Shalev
ronny@dyadmed.com

Logo - https://mma.prnewswire.com/media/1295323/Dyad_Medical_Logo.jpg

© 2020 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.